-
Aptar nasal system delivers FDA-approved heart rhythm drug CARDAMYST
-
Increasing unusual option volume: MIST APPN NXDR IRBT XPO FLWS ENTG FBIO FND
-
TD Cowen Upgrades Milestone Pharmaceuticals (MIST) to Buy
-
Milestone Pharmaceuticals (MIST) PT Raised to $8 at H.C. Wainwright
-
Increasing unusual call option volume: CMA OCSL CVE NXDR SHOO LDOS RCUS MIST
-
Milestone Pharmaceuticals (MIST) PT Raised to $2 at Jefferies
-
Milestone Pharmaceuticals Inc. (MIST) Tops Q3 EPS by 4c
-
Wells Fargo Starts Milestone Pharmaceuticals (MIST) at Overweight
-
Milestone Pharmaceuticals prices $52.5 million public offering
-
Milestone Pharmaceuticals announces public offering of shares and warrants
-
Milestone Pharmaceuticals receives FDA acceptance for CARDAMYST response
-
H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
Milestone Pharmaceuticals Inc. (MIST) Submits Response to the FDA’s CRL for CARDAMYST
-
Milestone Pharmaceuticals Inc. (MIST) Misses Q1 EPS by 11c
-
TD Cowen Downgrades Milestone Pharmaceuticals (MIST) to Hold
-
Milestone Pharmaceuticals (MIST): FDA Issues Complete Response Letter for Etripamil for PSVT
-
Milestone Pharmaceuticals Inc. (MIST) Halted, News Pending
-
H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
Increasing unusual option volume: COMM MIST HNRG VERU QFIN
-
Milestone Pharmaceuticals Inc. (MIST) Misses Q4 EPS by 3c
-
Milestone Pharmaceuticals (MIST) Notice of Allowance on New U.S. Patent for Etripamil
-
Milestone Pharmaceuticals (MIST) Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
-
H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
Milestone Pharmaceuticals Inc. (MIST) Tops Q3 EPS by 2c
-
TD Cowen Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
TD Cowen Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
Milestone (MIST) Partner Ji Xing Pharmaceuticals Reports Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
-
Milestone Pharmaceuticals Inc. (MIST) Appoints Joseph Papa to its Board
-
Milestone Pharmaceuticals Inc. (MIST) Tops Q2 EPS by 5c
-
Milestone Pharmaceuticals Inc. (MIST) Announces Board Changes
-
H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)

